Statement Of Investor Complaints For The Quarter Ended March 2018 (Revised)
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 025250 Name of the Signatory :- K. Hanumantha RaoDesignation :- Company Secretary and Compliance Officer Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 025250 Name of the Signatory :- K. Hanumantha RaoDesignation :- Company Secretary and Compliance Officer Compliance Certificate Under Regulation 7(3) Of SEBI (LODR)Regulations, 2015 For The Half-Year Ended 31St March, 2018
Compliance certificate for the half-year ended 31st March, 2018 duly signed by the Compliance Officer and authorised representative of the share transfer agent (Karvy Computershare Pvt. Ltd., Hyderabad), under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Shareholding for the Period Ended March 31, 2018
Suven Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here Submission Of Compliance Certificate Under Regulation 40(10) For The Half-Year Ended 31St March, 2018
Pease find enclosed Compliance Certificate for the half-year ended 31st March, 2018 issued by the Practicing Company Secretary, under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015. Suven Life gets product patent for neurodegenerative disorders
Suven Life Sciences has been granted a product patent by Canada corresponding to new chemical entities (NCEs) for the treatment of disorders associa Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences secures a Product Patent in Canada Suven Life Sciences Limited
on Thursday announced the grant of one product patent from Norway, another from South Korea and a third from Singapore for new chemical entities (NCEs) for the treatment of disorders associated wit Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences secures Product Patents in Norway, South Korea and Singapore Suven gets product patents from India, South Korea
Suven Life Sciences has secured a product patent each from India and South Korea for treatment of disorders associated with neuro-degenerative diseases. The patents are valid through 2029 and 2033